カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の組換えヒトインターロイキン2注射市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Recombinant Human Interleukin 2 Injection Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19598）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19598
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：95
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の組換えヒトインターロイキン2注射市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

組換えヒトインターロイキン2注射市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の組換えヒトインターロイキン2注射の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

組換えヒトインターロイキン2注射市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・50000U、100000U、200000U、500000U、100万U、その他

用途別セグメントは次のように区分されます。
・病院、薬局

世界の組換えヒトインターロイキン2注射市場の主要な市場プレーヤーは以下のとおりです。
・Jiangsu Jinsili Pharmaceutical、3SBio、Beijing SL Pharm、Shanghai Huaxin Biology Gaojishu、Beijing Four Rings Biopharmaceutical、Beijing Yuance Pharmaceutical、Shandong Quangang Pharmaceutical

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、組換えヒトインターロイキン2注射製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な組換えヒトインターロイキン2注射メーカーの企業概要、2019年～2022年までの組換えヒトインターロイキン2注射の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な組換えヒトインターロイキン2注射メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別組換えヒトインターロイキン2注射の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの組換えヒトインターロイキン2注射の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での組換えヒトインターロイキン2注射市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および組換えヒトインターロイキン2注射の産業チェーンを掲載しています。
・第13、14、15章では、組換えヒトインターロイキン2注射の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 組換えヒトインターロイキン2注射の概要
- 種類別分析（2017年vs2021年vs2028年）：50000U、100000U、200000U、500000U、100万U、その他
- 用途別分析（2017年vs2021年vs2028年）：病院、薬局
- 世界の組換えヒトインターロイキン2注射市場規模・予測
- 世界の組換えヒトインターロイキン2注射生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Jiangsu Jinsili Pharmaceutical、3SBio、Beijing SL Pharm、Shanghai Huaxin Biology Gaojishu、Beijing Four Rings Biopharmaceutical、Beijing Yuance Pharmaceutical、Shandong Quangang Pharmaceutical
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：50000U、100000U、200000U、500000U、100万U、その他
・用途別分析2017年-2028年：病院、薬局
・組換えヒトインターロイキン2注射の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・組換えヒトインターロイキン2注射のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・組換えヒトインターロイキン2注射のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・組換えヒトインターロイキン2注射の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・組換えヒトインターロイキン2注射の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Recombinant Human Interleukin 2 Injection market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Recombinant Human Interleukin 2 Injection market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Recombinant Human Interleukin 2 Injection global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 50000 U segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Recombinant Human Interleukin 2 Injection include Jiangsu Jinsili Pharmaceutical, 3SBio, Beijing SL Pharm, Shanghai Huaxin Biology Gaojishu, and Beijing Four Rings Biopharmaceutical, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Recombinant Human Interleukin 2 Injection market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
50000 U
100000 U
200000 U
500000 U
1 Million U
Other
Market segment by Application can be divided into
Hospital
Pharmacy
The key market players for global Recombinant Human Interleukin 2 Injection market are listed below:
Jiangsu Jinsili Pharmaceutical
3SBio
Beijing SL Pharm
Shanghai Huaxin Biology Gaojishu
Beijing Four Rings Biopharmaceutical
Beijing Yuance Pharmaceutical
Shandong Quangang Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Human Interleukin 2 Injection product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Recombinant Human Interleukin 2 Injection, with price, sales, revenue and global market share of Recombinant Human Interleukin 2 Injection from 2019 to 2022.
Chapter 3, the Recombinant Human Interleukin 2 Injection competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Human Interleukin 2 Injection breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Recombinant Human Interleukin 2 Injection market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant Human Interleukin 2 Injection.
Chapter 13, 14, and 15, to describe Recombinant Human Interleukin 2 Injection sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Recombinant Human Interleukin 2 Injection Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Recombinant Human Interleukin 2 Injection Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 50000 U
1.2.3 100000 U
1.2.4 200000 U
1.2.5 500000 U
1.2.6 1 Million U
1.2.7 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Recombinant Human Interleukin 2 Injection Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Recombinant Human Interleukin 2 Injection Market Size & Forecast
1.4.1 Global Recombinant Human Interleukin 2 Injection Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Recombinant Human Interleukin 2 Injection Sales in Volume (2017-2028)
1.4.3 Global Recombinant Human Interleukin 2 Injection Price (2017-2028)
1.5 Global Recombinant Human Interleukin 2 Injection Production Capacity Analysis
1.5.1 Global Recombinant Human Interleukin 2 Injection Total Production Capacity (2017-2028)
1.5.2 Global Recombinant Human Interleukin 2 Injection Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Recombinant Human Interleukin 2 Injection Market Drivers
1.6.2 Recombinant Human Interleukin 2 Injection Market Restraints
1.6.3 Recombinant Human Interleukin 2 Injection Trends Analysis
2 Manufacturers Profiles
2.1 Jiangsu Jinsili Pharmaceutical
2.1.1 Jiangsu Jinsili Pharmaceutical Details
2.1.2 Jiangsu Jinsili Pharmaceutical Major Business
2.1.3 Jiangsu Jinsili Pharmaceutical Recombinant Human Interleukin 2 Injection Product and Services
2.1.4 Jiangsu Jinsili Pharmaceutical Recombinant Human Interleukin 2 Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 3SBio
2.2.1 3SBio Details
2.2.2 3SBio Major Business
2.2.3 3SBio Recombinant Human Interleukin 2 Injection Product and Services
2.2.4 3SBio Recombinant Human Interleukin 2 Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Beijing SL Pharm
2.3.1 Beijing SL Pharm Details
2.3.2 Beijing SL Pharm Major Business
2.3.3 Beijing SL Pharm Recombinant Human Interleukin 2 Injection Product and Services
2.3.4 Beijing SL Pharm Recombinant Human Interleukin 2 Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Shanghai Huaxin Biology Gaojishu
2.4.1 Shanghai Huaxin Biology Gaojishu Details
2.4.2 Shanghai Huaxin Biology Gaojishu Major Business
2.4.3 Shanghai Huaxin Biology Gaojishu Recombinant Human Interleukin 2 Injection Product and Services
2.4.4 Shanghai Huaxin Biology Gaojishu Recombinant Human Interleukin 2 Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Beijing Four Rings Biopharmaceutical
2.5.1 Beijing Four Rings Biopharmaceutical Details
2.5.2 Beijing Four Rings Biopharmaceutical Major Business
2.5.3 Beijing Four Rings Biopharmaceutical Recombinant Human Interleukin 2 Injection Product and Services
2.5.4 Beijing Four Rings Biopharmaceutical Recombinant Human Interleukin 2 Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Beijing Yuance Pharmaceutical
2.6.1 Beijing Yuance Pharmaceutical Details
2.6.2 Beijing Yuance Pharmaceutical Major Business
2.6.3 Beijing Yuance Pharmaceutical Recombinant Human Interleukin 2 Injection Product and Services
2.6.4 Beijing Yuance Pharmaceutical Recombinant Human Interleukin 2 Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Shandong Quangang Pharmaceutical
2.7.1 Shandong Quangang Pharmaceutical Details
2.7.2 Shandong Quangang Pharmaceutical Major Business
2.7.3 Shandong Quangang Pharmaceutical Recombinant Human Interleukin 2 Injection Product and Services
2.7.4 Shandong Quangang Pharmaceutical Recombinant Human Interleukin 2 Injection Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Recombinant Human Interleukin 2 Injection Breakdown Data by Manufacturer
3.1 Global Recombinant Human Interleukin 2 Injection Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Recombinant Human Interleukin 2 Injection Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Recombinant Human Interleukin 2 Injection
3.4 Market Concentration Rate
3.4.1 Top 3 Recombinant Human Interleukin 2 Injection Manufacturer Market Share in 2021
3.4.2 Top 6 Recombinant Human Interleukin 2 Injection Manufacturer Market Share in 2021
3.5 Global Recombinant Human Interleukin 2 Injection Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Recombinant Human Interleukin 2 Injection Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Recombinant Human Interleukin 2 Injection Market Size by Region
4.1.1 Global Recombinant Human Interleukin 2 Injection Sales in Volume by Region (2017-2028)
4.1.2 Global Recombinant Human Interleukin 2 Injection Revenue by Region (2017-2028)
4.2 North America Recombinant Human Interleukin 2 Injection Revenue (2017-2028)
4.3 Europe Recombinant Human Interleukin 2 Injection Revenue (2017-2028)
4.4 Asia-Pacific Recombinant Human Interleukin 2 Injection Revenue (2017-2028)
4.5 South America Recombinant Human Interleukin 2 Injection Revenue (2017-2028)
4.6 Middle East and Africa Recombinant Human Interleukin 2 Injection Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Recombinant Human Interleukin 2 Injection Sales in Volume by Type (2017-2028)
5.2 Global Recombinant Human Interleukin 2 Injection Revenue by Type (2017-2028)
5.3 Global Recombinant Human Interleukin 2 Injection Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Recombinant Human Interleukin 2 Injection Sales in Volume by Application (2017-2028)
6.2 Global Recombinant Human Interleukin 2 Injection Revenue by Application (2017-2028)
6.3 Global Recombinant Human Interleukin 2 Injection Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Recombinant Human Interleukin 2 Injection Sales by Type (2017-2028)
7.2 North America Recombinant Human Interleukin 2 Injection Sales by Application (2017-2028)
7.3 North America Recombinant Human Interleukin 2 Injection Market Size by Country
7.3.1 North America Recombinant Human Interleukin 2 Injection Sales in Volume by Country (2017-2028)
7.3.2 North America Recombinant Human Interleukin 2 Injection Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Recombinant Human Interleukin 2 Injection Sales by Type (2017-2028)
8.2 Europe Recombinant Human Interleukin 2 Injection Sales by Application (2017-2028)
8.3 Europe Recombinant Human Interleukin 2 Injection Market Size by Country
8.3.1 Europe Recombinant Human Interleukin 2 Injection Sales in Volume by Country (2017-2028)
8.3.2 Europe Recombinant Human Interleukin 2 Injection Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Recombinant Human Interleukin 2 Injection Sales by Type (2017-2028)
9.2 Asia-Pacific Recombinant Human Interleukin 2 Injection Sales by Application (2017-2028)
9.3 Asia-Pacific Recombinant Human Interleukin 2 Injection Market Size by Region
9.3.1 Asia-Pacific Recombinant Human Interleukin 2 Injection Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Recombinant Human Interleukin 2 Injection Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Recombinant Human Interleukin 2 Injection Sales by Type (2017-2028)
10.2 South America Recombinant Human Interleukin 2 Injection Sales by Application (2017-2028)
10.3 South America Recombinant Human Interleukin 2 Injection Market Size by Country
10.3.1 South America Recombinant Human Interleukin 2 Injection Sales in Volume by Country (2017-2028)
10.3.2 South America Recombinant Human Interleukin 2 Injection Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Recombinant Human Interleukin 2 Injection Sales by Type (2017-2028)
11.2 Middle East & Africa Recombinant Human Interleukin 2 Injection Sales by Application (2017-2028)
11.3 Middle East & Africa Recombinant Human Interleukin 2 Injection Market Size by Country
11.3.1 Middle East & Africa Recombinant Human Interleukin 2 Injection Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Recombinant Human Interleukin 2 Injection Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Recombinant Human Interleukin 2 Injection and Key Manufacturers
12.2 Manufacturing Costs Percentage of Recombinant Human Interleukin 2 Injection
12.3 Recombinant Human Interleukin 2 Injection Production Process
12.4 Recombinant Human Interleukin 2 Injection Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Recombinant Human Interleukin 2 Injection Typical Distributors
13.3 Recombinant Human Interleukin 2 Injection Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Recombinant Human Interleukin 2 Injection Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Recombinant Human Interleukin 2 Injection Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Jiangsu Jinsili Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 4. Jiangsu Jinsili Pharmaceutical Major Business
Table 5. Jiangsu Jinsili Pharmaceutical Recombinant Human Interleukin 2 Injection Product and Services
Table 6. Jiangsu Jinsili Pharmaceutical Recombinant Human Interleukin 2 Injection Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. 3SBio Basic Information, Manufacturing Base and Competitors
Table 8. 3SBio Major Business
Table 9. 3SBio Recombinant Human Interleukin 2 Injection Product and Services
Table 10. 3SBio Recombinant Human Interleukin 2 Injection Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Beijing SL Pharm Basic Information, Manufacturing Base and Competitors
Table 12. Beijing SL Pharm Major Business
Table 13. Beijing SL Pharm Recombinant Human Interleukin 2 Injection Product and Services
Table 14. Beijing SL Pharm Recombinant Human Interleukin 2 Injection Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Shanghai Huaxin Biology Gaojishu Basic Information, Manufacturing Base and Competitors
Table 16. Shanghai Huaxin Biology Gaojishu Major Business
Table 17. Shanghai Huaxin Biology Gaojishu Recombinant Human Interleukin 2 Injection Product and Services
Table 18. Shanghai Huaxin Biology Gaojishu Recombinant Human Interleukin 2 Injection Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Beijing Four Rings Biopharmaceutical Basic Information, Manufacturing Base and Competitors
Table 20. Beijing Four Rings Biopharmaceutical Major Business
Table 21. Beijing Four Rings Biopharmaceutical Recombinant Human Interleukin 2 Injection Product and Services
Table 22. Beijing Four Rings Biopharmaceutical Recombinant Human Interleukin 2 Injection Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Beijing Yuance Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 24. Beijing Yuance Pharmaceutical Major Business
Table 25. Beijing Yuance Pharmaceutical Recombinant Human Interleukin 2 Injection Product and Services
Table 26. Beijing Yuance Pharmaceutical Recombinant Human Interleukin 2 Injection Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Shandong Quangang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 28. Shandong Quangang Pharmaceutical Major Business
Table 29. Shandong Quangang Pharmaceutical Recombinant Human Interleukin 2 Injection Product and Services
Table 30. Shandong Quangang Pharmaceutical Recombinant Human Interleukin 2 Injection Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Global Recombinant Human Interleukin 2 Injection Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 32. Global Recombinant Human Interleukin 2 Injection Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 33. Market Position of Manufacturers in Recombinant Human Interleukin 2 Injection, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 34. Global Recombinant Human Interleukin 2 Injection Production Capacity by Company, (K Units): 2020 VS 2021
Table 35. Head Office and Recombinant Human Interleukin 2 Injection Production Site of Key Manufacturer
Table 36. Recombinant Human Interleukin 2 Injection New Entrant and Capacity Expansion Plans
Table 37. Recombinant Human Interleukin 2 Injection Mergers & Acquisitions in the Past Five Years
Table 38. Global Recombinant Human Interleukin 2 Injection Sales by Region (2017-2022) & (K Units)
Table 39. Global Recombinant Human Interleukin 2 Injection Sales by Region (2023-2028) & (K Units)
Table 40. Global Recombinant Human Interleukin 2 Injection Revenue by Region (2017-2022) & (USD Million)
Table 41. Global Recombinant Human Interleukin 2 Injection Revenue by Region (2023-2028) & (USD Million)
Table 42. Global Recombinant Human Interleukin 2 Injection Sales by Type (2017-2022) & (K Units)
Table 43. Global Recombinant Human Interleukin 2 Injection Sales by Type (2023-2028) & (K Units)
Table 44. Global Recombinant Human Interleukin 2 Injection Revenue by Type (2017-2022) & (USD Million)
Table 45. Global Recombinant Human Interleukin 2 Injection Revenue by Type (2023-2028) & (USD Million)
Table 46. Global Recombinant Human Interleukin 2 Injection Price by Type (2017-2022) & (US$/Unit)
Table 47. Global Recombinant Human Interleukin 2 Injection Price by Type (2023-2028) & (US$/Unit)
Table 48. Global Recombinant Human Interleukin 2 Injection Sales by Application (2017-2022) & (K Units)
Table 49. Global Recombinant Human Interleukin 2 Injection Sales by Application (2023-2028) & (K Units)
Table 50. Global Recombinant Human Interleukin 2 Injection Revenue by Application (2017-2022) & (USD Million)
Table 51. Global Recombinant Human Interleukin 2 Injection Revenue by Application (2023-2028) & (USD Million)
Table 52. Global Recombinant Human Interleukin 2 Injection Price by Application (2017-2022) & (US$/Unit)
Table 53. Global Recombinant Human Interleukin 2 Injection Price by Application (2023-2028) & (US$/Unit)
Table 54. North America Recombinant Human Interleukin 2 Injection Sales by Country (2017-2022) & (K Units)
Table 55. North America Recombinant Human Interleukin 2 Injection Sales by Country (2023-2028) & (K Units)
Table 56. North America Recombinant Human Interleukin 2 Injection Revenue by Country (2017-2022) & (USD Million)
Table 57. North America Recombinant Human Interleukin 2 Injection Revenue by Country (2023-2028) & (USD Million)
Table 58. North America Recombinant Human Interleukin 2 Injection Sales by Type (2017-2022) & (K Units)
Table 59. North America Recombinant Human Interleukin 2 Injection Sales by Type (2023-2028) & (K Units)
Table 60. North America Recombinant Human Interleukin 2 Injection Sales by Application (2017-2022) & (K Units)
Table 61. North America Recombinant Human Interleukin 2 Injection Sales by Application (2023-2028) & (K Units)
Table 62. Europe Recombinant Human Interleukin 2 Injection Sales by Country (2017-2022) & (K Units)
Table 63. Europe Recombinant Human Interleukin 2 Injection Sales by Country (2023-2028) & (K Units)
Table 64. Europe Recombinant Human Interleukin 2 Injection Revenue by Country (2017-2022) & (USD Million)
Table 65. Europe Recombinant Human Interleukin 2 Injection Revenue by Country (2023-2028) & (USD Million)
Table 66. Europe Recombinant Human Interleukin 2 Injection Sales by Type (2017-2022) & (K Units)
Table 67. Europe Recombinant Human Interleukin 2 Injection Sales by Type (2023-2028) & (K Units)
Table 68. Europe Recombinant Human Interleukin 2 Injection Sales by Application (2017-2022) & (K Units)
Table 69. Europe Recombinant Human Interleukin 2 Injection Sales by Application (2023-2028) & (K Units)
Table 70. Asia-Pacific Recombinant Human Interleukin 2 Injection Sales by Region (2017-2022) & (K Units)
Table 71. Asia-Pacific Recombinant Human Interleukin 2 Injection Sales by Region (2023-2028) & (K Units)
Table 72. Asia-Pacific Recombinant Human Interleukin 2 Injection Revenue by Region (2017-2022) & (USD Million)
Table 73. Asia-Pacific Recombinant Human Interleukin 2 Injection Revenue by Region (2023-2028) & (USD Million)
Table 74. Asia-Pacific Recombinant Human Interleukin 2 Injection Sales by Type (2017-2022) & (K Units)
Table 75. Asia-Pacific Recombinant Human Interleukin 2 Injection Sales by Type (2023-2028) & (K Units)
Table 76. Asia-Pacific Recombinant Human Interleukin 2 Injection Sales by Application (2017-2022) & (K Units)
Table 77. Asia-Pacific Recombinant Human Interleukin 2 Injection Sales by Application (2023-2028) & (K Units)
Table 78. South America Recombinant Human Interleukin 2 Injection Sales by Country (2017-2022) & (K Units)
Table 79. South America Recombinant Human Interleukin 2 Injection Sales by Country (2023-2028) & (K Units)
Table 80. South America Recombinant Human Interleukin 2 Injection Revenue by Country (2017-2022) & (USD Million)
Table 81. South America Recombinant Human Interleukin 2 Injection Revenue by Country (2023-2028) & (USD Million)
Table 82. South America Recombinant Human Interleukin 2 Injection Sales by Type (2017-2022) & (K Units)
Table 83. South America Recombinant Human Interleukin 2 Injection Sales by Type (2023-2028) & (K Units)
Table 84. South America Recombinant Human Interleukin 2 Injection Sales by Application (2017-2022) & (K Units)
Table 85. South America Recombinant Human Interleukin 2 Injection Sales by Application (2023-2028) & (K Units)
Table 86. Middle East & Africa Recombinant Human Interleukin 2 Injection Sales by Region (2017-2022) & (K Units)
Table 87. Middle East & Africa Recombinant Human Interleukin 2 Injection Sales by Region (2023-2028) & (K Units)
Table 88. Middle East & Africa Recombinant Human Interleukin 2 Injection Revenue by Region (2017-2022) & (USD Million)
Table 89. Middle East & Africa Recombinant Human Interleukin 2 Injection Revenue by Region (2023-2028) & (USD Million)
Table 90. Middle East & Africa Recombinant Human Interleukin 2 Injection Sales by Type (2017-2022) & (K Units)
Table 91. Middle East & Africa Recombinant Human Interleukin 2 Injection Sales by Type (2023-2028) & (K Units)
Table 92. Middle East & Africa Recombinant Human Interleukin 2 Injection Sales by Application (2017-2022) & (K Units)
Table 93. Middle East & Africa Recombinant Human Interleukin 2 Injection Sales by Application (2023-2028) & (K Units)
Table 94. Recombinant Human Interleukin 2 Injection Raw Material
Table 95. Key Manufacturers of Recombinant Human Interleukin 2 Injection Raw Materials
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. Recombinant Human Interleukin 2 Injection Typical Distributors
Table 99. Recombinant Human Interleukin 2 Injection Typical Customers
List of Figures
Figure 1. Recombinant Human Interleukin 2 Injection Picture
Figure 2. Global Recombinant Human Interleukin 2 Injection Revenue Market Share by Type in 2021
Figure 3. 50000 U
Figure 4. 100000 U
Figure 5. 200000 U
Figure 6. 500000 U
Figure 7. 1 Million U
Figure 8. Other
Figure 9. Global Recombinant Human Interleukin 2 Injection Revenue Market Share by Application in 2021
Figure 10. Hospital
Figure 11. Pharmacy
Figure 12. Global Recombinant Human Interleukin 2 Injection Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 13. Global Recombinant Human Interleukin 2 Injection Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Recombinant Human Interleukin 2 Injection Sales (2017-2028) & (K Units)
Figure 15. Global Recombinant Human Interleukin 2 Injection Price (2017-2028) & (US$/Unit)
Figure 16. Global Recombinant Human Interleukin 2 Injection Production Capacity (2017-2028) & (K Units)
Figure 17. Global Recombinant Human Interleukin 2 Injection Production Capacity by Geographic Region: 2022 VS 2028
Figure 18. Recombinant Human Interleukin 2 Injection Market Drivers
Figure 19. Recombinant Human Interleukin 2 Injection Market Restraints
Figure 20. Recombinant Human Interleukin 2 Injection Market Trends
Figure 21. Global Recombinant Human Interleukin 2 Injection Sales Market Share by Manufacturer in 2021
Figure 22. Global Recombinant Human Interleukin 2 Injection Revenue Market Share by Manufacturer in 2021
Figure 23. Recombinant Human Interleukin 2 Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 24. Top 3 Recombinant Human Interleukin 2 Injection Manufacturer (Revenue) Market Share in 2021
Figure 25. Top 6 Recombinant Human Interleukin 2 Injection Manufacturer (Revenue) Market Share in 2021
Figure 26. Global Recombinant Human Interleukin 2 Injection Sales Market Share by Region (2017-2028)
Figure 27. Global Recombinant Human Interleukin 2 Injection Revenue Market Share by Region (2017-2028)
Figure 28. North America Recombinant Human Interleukin 2 Injection Revenue (2017-2028) & (USD Million)
Figure 29. Europe Recombinant Human Interleukin 2 Injection Revenue (2017-2028) & (USD Million)
Figure 30. Asia-Pacific Recombinant Human Interleukin 2 Injection Revenue (2017-2028) & (USD Million)
Figure 31. South America Recombinant Human Interleukin 2 Injection Revenue (2017-2028) & (USD Million)
Figure 32. Middle East & Africa Recombinant Human Interleukin 2 Injection Revenue (2017-2028) & (USD Million)
Figure 33. Global Recombinant Human Interleukin 2 Injection Sales Market Share by Type (2017-2028)
Figure 34. Global Recombinant Human Interleukin 2 Injection Revenue Market Share by Type (2017-2028)
Figure 35. Global Recombinant Human Interleukin 2 Injection Price by Type (2017-2028) & (US$/Unit)
Figure 36. Global Recombinant Human Interleukin 2 Injection Sales Market Share by Application (2017-2028)
Figure 37. Global Recombinant Human Interleukin 2 Injection Revenue Market Share by Application (2017-2028)
Figure 38. Global Recombinant Human Interleukin 2 Injection Price by Application (2017-2028) & (US$/Unit)
Figure 39. North America Recombinant Human Interleukin 2 Injection Sales Market Share by Type (2017-2028)
Figure 40. North America Recombinant Human Interleukin 2 Injection Sales Market Share by Application (2017-2028)
Figure 41. North America Recombinant Human Interleukin 2 Injection Sales Market Share by Country (2017-2028)
Figure 42. North America Recombinant Human Interleukin 2 Injection Revenue Market Share by Country (2017-2028)
Figure 43. United States Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Canada Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Mexico Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Europe Recombinant Human Interleukin 2 Injection Sales Market Share by Type (2017-2028)
Figure 47. Europe Recombinant Human Interleukin 2 Injection Sales Market Share by Application (2017-2028)
Figure 48. Europe Recombinant Human Interleukin 2 Injection Sales Market Share by Country (2017-2028)
Figure 49. Europe Recombinant Human Interleukin 2 Injection Revenue Market Share by Country (2017-2028)
Figure 50. Germany Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific Recombinant Human Interleukin 2 Injection Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Recombinant Human Interleukin 2 Injection Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific Recombinant Human Interleukin 2 Injection Sales Market Share by Region (2017-2028)
Figure 58. Asia-Pacific Recombinant Human Interleukin 2 Injection Revenue Market Share by Region (2017-2028)
Figure 59. China Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Korea Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Recombinant Human Interleukin 2 Injection Sales Market Share by Type (2017-2028)
Figure 66. South America Recombinant Human Interleukin 2 Injection Sales Market Share by Application (2017-2028)
Figure 67. South America Recombinant Human Interleukin 2 Injection Sales Market Share by Country (2017-2028)
Figure 68. South America Recombinant Human Interleukin 2 Injection Revenue Market Share by Country (2017-2028)
Figure 69. Brazil Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East & Africa Recombinant Human Interleukin 2 Injection Sales Market Share by Type (2017-2028)
Figure 72. Middle East & Africa Recombinant Human Interleukin 2 Injection Sales Market Share by Application (2017-2028)
Figure 73. Middle East & Africa Recombinant Human Interleukin 2 Injection Sales Market Share by Region (2017-2028)
Figure 74. Middle East & Africa Recombinant Human Interleukin 2 Injection Revenue Market Share by Region (2017-2028)
Figure 75. Turkey Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Egypt Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Saudi Arabia Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. South Africa Recombinant Human Interleukin 2 Injection Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Manufacturing Cost Structure Analysis of Recombinant Human Interleukin 2 Injection in 2021
Figure 80. Manufacturing Process Analysis of Recombinant Human Interleukin 2 Injection
Figure 81. Recombinant Human Interleukin 2 Injection Industrial Chain
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
Figure 83. Methodology
Figure 84. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 注射用組換えヒトソマトロピンのグローバル市場展望 2023年-2029年：粉体射出、水系射出
  • 組換えヒトパピローマウイルス9価ワクチンのグローバル市場展望 2023年-2029年：女性、男性
  • 組換えヒト凝固VIIaの世界市場2023年：プレフィルドシリンジ、バイアル
  • 遺伝子組み換えコラーゲン医療美容注射のグローバル市場展望 2023年-2029年：植物由来コラーゲン、動物由来コラーゲン
  • ヒト注射用インフルエンザワクチンのグローバル市場展望 2023年-2029年：3価インフルエンザワクチン、4価インフルエンザワクチン
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19598 )"世界の組換えヒトインターロイキン2注射市場2022年：市場規模予測（～2028年）" (英文：Global Recombinant Human Interleukin 2 Injection Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。